This scenario has undergone major changes since the advent of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis), highly effective drugs for patients with BRCA1/2 gene mutations and/or homologous recombination deficiency (HRD) ovarian cancer (Moore et al., 2018). The gene discussed is BRCA1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.